What other drugs will affect this medicine
See my PepPal news coverage of the FDA February 2026 ruling for context on what changed
Using the same area might also make it harder for your body to absorb the medicine
Your provider will review your health to support your individual needs
According to NICE guidance (NG28), the continuation of GLP-1 receptor agonist therapy in type 2 diabetes should be assessed after six months, with treatment continued only if there is a reduction in HbA1c of at least 11 mmol/mol (1%) and, where applicable, a weight loss of at least 3% of initial body weight
Of critical interest here: based on the brisk pace at which lower airway infections often ensue after the emergence of initial symptoms, it has been conjectured that the nasopharynx also acts as the seeding zone for the spread of a respiratory viral disease to the lungs via lower airway aspiration of virus-laden boluses of nasopharyngeal fluids (Hou et al., 2020